Messing with HIV

Sangamo Biosciences is putting a different spin on gene therapy. 

Jef Akst
Jef Akst

Jef Akst is managing editor of The Scientist, where she started as an intern in 2009 after receiving a master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses.

View full profile.


Learn about our editorial policies.

Jun 1, 2012

Infographic: Messing with HIV
View full size JPG | PDF
LUCY READING-IKKANDA

Sangamo Biosciences is putting a different spin on gene therapy. Rather than replace or supplement a mutated gene with an accurate copy, Sangamo researchers are introducing a mutant copy of the gene for the HIV co-receptor CCR5 into the T cells of HIV patients. This prevents the expression of CCR5 on the cell’s surface, and thus inhibits HIV from infecting cells.

Read the full story.

Interested in reading more?

Magaizne Cover

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?